Trabectedin is recommended as a possible treatment for people with advanced soft tissue sarcoma if:
- treatment with anthracyclines and ifosfamide has failed, or
- they cannot tolerate anthracyclines and ifosfamide, or
- anthracyclines and ifosfamide are unsuitable.
The manufacturer of trabectedin has agreed to a 'patient access scheme', which means that when a person needs more than five trabectedin treatments, it provides the sixth and any further trabectedin treatments to the NHS free of charge.